| Budget Amount *help |
¥2,353,000 (Direct Cost: ¥1,810,000、Indirect Cost: ¥543,000)
Fiscal Year 2010: ¥1,261,000 (Direct Cost: ¥970,000、Indirect Cost: ¥291,000)
Fiscal Year 2009: ¥1,092,000 (Direct Cost: ¥840,000、Indirect Cost: ¥252,000)
|
|---|
| Research Abstract |
We conducted a study to determine the utility of contrast-enhanced ultrasonography (CE US) as a prognostic tool for advanced hepatocellular carcinoma (HCC) patients receiving sorafenib and to identify CE US parameters that correlate with early treatment response. As a results, CE US can be used to quantify dynamic changes in tumor vascularity as early as several days after sorafenib administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 1 month, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.
|
